Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Significant new investment will fund the R&D focus of Collagen Solutions, says CEO

It has unveiled plans to raise as much as £12mln, which should transform the business.
Significant new investment will fund the R&D focus of Collagen Solutions, says CEO
Knee pain? The company's ChondroMimetic scaffold is designed to stimulate the regeneration of both joint cartilage and the underlying bone

Collagen Solutions PLC (LON:COS) is planning to raise up to £12mln by issuing equity and debt, which will help accelerate the growth of the business.

It is raising the bulk of the new monies from investors via a placing and open offer that could bring in as much as £8mln.

A further £4mln will provided by finance house Norgine Ventures, which will subscribe to bonds with warrants attached.

Chief executive Jamal Rushdy called the funding round “strategically important”.

The cash will be used to develop and launch new, higher value “finished device products”, which will supplement the revenues from base business – the supply of bovine collagen materials.

As the company pointed out in its statement, while the revenue stream from the current operation is stable and long-term, the sales cycle is often “long and complex”.

Investing in R&D

So, Collagen Solutions is moving up the value chain with products such ChondroMimetic, an implant used to treat cartilage and underlying bone defects.

It also plans to go ahead with bone graft and wound treatment collagen devices.

“Mostly we are investing research and development to complete and successfully commercialise regenerative medicine/finished device products,” CEO Rushdy told Proactive Investors.

“So that’s where most of our focus is going to be.

“However, we are also using some of the funds to accelerate our core business; completing our investment in sales, marketing and some of the back-end infrastructure we need to support our growth in bio-materials and tissue supply.”

Boardroom support 

Interesting is the scale of boardroom financial support for the strategy, evidenced by the £1mln being contributed by Collagen’s directors.

A total of £825,000 is coming from chairman and serial healthcare entrepreneur David Evans.

The equity portion of the fundraise could almost double the Collagen’s share base.

Usually that would result in a mark-down in the stock, which is being sold to new and existing investors for 5p.

In early afternoon trade, the shares were 3% higher and changing hands for 5.7p each.

Broker excited 

City broker Cenkos said Collagen now has now has more than enough cash to see it through to a “self-sustaining cash flow positive situation”.

It previously said the business required around £6mln to get it to this position.

Analyst Chris Donnellan highlighted the huge potential of Collagen Solutions’ ChondroMimetic scaffold, which is designed to stimulate the regeneration of both joint cartilage and the underlying bone in patients with joint damage.

The product should receive regulatory sign off later this year and is likely to be sold by a third party via a distribution agreement.

Estimates suggest that there are more than 250,000 cartilage procedures performed annually in the US.

Here in Europe, meanwhile, the opportunity could be £340mln (€400mln), Cenkos’s Donnellan reckons.

Even if it were to capture 5% of market share when established, that would still equate to £17mln of annual revenues, or around five times' Collagen Solutions’ current turnover.

“We do not believe the current share price reflects the company’s ambition to grow its revenues by five-times over five-years, nor the full potential of the ChondroMimetic regenerative medicine scaffold,” said Donnellan, reiterating his ‘buy’ recommendation.


View full COS profile View Profile

Collagen Solutions PLC Timeline

Related Articles

Drug discovery
April 04 2018
In the group’s 2017 results statement at the end of March, Ray Barlow - who took over as CEO on 6 April 2017 - commented: “We are now focused on the right activities"
Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use